Advisory

Learn MoreFREE TRIAL

CSL is navigating a period of significant structural transition and market re-evaluation. The stock recently hit a nine-year low, primarily driven by a sharp earnings reset in its half-year results and broader regulatory headwinds.

Valuation: The price-to-earnings (P/E) ratio has compressed to approximately 15x (TTM) on an underlying basis.

Recent Financial Performance (H1 FY26)
The company’s February 2026 earnings report was a major catalyst for the recent sell-off:

• Net Profit Plunge: Reported Net Profit After Tax (NPAT) fell 81% to US$401 million, largely due to ~US$1.1 billion in one-off restructuring charges and asset impairments.
• Underlying Performance: Underlying NPATA fell 7% to US$1.9 billion.
• Revenue: Declined 4% to US$8.3 billion (constant currency). The core CSL Behring plasma division saw a 7% sales contraction, driven by U.S. Medicare reimbursement reforms and policy changes in China affecting pricing.
• Impairments: Significant write-downs were taken on CSL Vifor (primarily due to generic competition for its iron therapy, Venofer®) and intellectual property within CSL Seqirus.

Strategic Developments & Recovery Plan
Despite the earnings volatility, management is aggressively deploying capital to stabilize margins:

• Capacity Expansion: In March 2026, CSL broke ground on a US$1.5 billion expansion of its Kankakee, Illinois facility. This project will utilize “Horizon 2” technology designed to increase protein yield from plasma.
• Share Buy-back: CSL is currently active in an on-market share buy-back program. As of today, April 27, 2026, the company has repurchased nearly 6 million shares to support shareholder value.
• Cost Savings: CSL has targeted US$500M+ in annual pre-tax savings by FY28 through organizational simplification.
• Vaccine Pipeline: CSL Seqirus recently secured new long-term contracts with the Pan American Health Organization (PAHO) and Canada for pandemic influenza preparedness.

Dividends & Guidance

• Dividends: The interim dividend of US$1.30 per share (unfranked) was paid on April 8, 2026. The current annual yield sits at approximately 3.3%.
• FY26 Outlook: Management has maintained guidance for the full year 2026, expecting 2–3% revenue growth and 4–7% NPATA growth (excluding one-offs). However, the market remains cautious about the “structural” nature of margin pressures through FY28.

Investor Outlook
The current market sentiment is a battle between value seekers (pointing to “oversold” technical indicators and a 15-year low multiple) and skeptics concerned about the long-term impact of U.S. Medicare drug price negotiations and competition in the iron deficiency market.